caa a22 4500 445794747 CHVBK 20180317145121.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1007/s10620-011-1761-4 doi (NATIONALLICENCE)springer-10.1007/s10620-011-1761-4 Serum sTREM-1 as a Surrogate Marker of Treatment Outcome in Patients with Peptic Ulcer Disease [Elektronische Daten] [Vassilios Koussoulas, Evangelos Giamarellos-Bourboulis, Charalambos Barbatzas, Mark Pimentel] Objective: Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is elevated in the gastric juice and in cultures of gastric mucosa of patients with peptic ulcer disease (PUD). Its application as a surrogate marker for the treatment of PUD was assessed. Methods: From 138 eligible patients, 96 were enrolled; 50 with duodenal ulcer, 29 with gastric ulcer and 17 with chronic gastritis. Patients were endoscoped twice; once before treatment and once after treatment. Biopsy specimens were collected for histopathologic estimation of gastritis. Blood was sampled prior to each endoscopy. Serum was collected and sTREM-1 was measured by an enzyme immunoabsorbent assay ( http://www.clinicaltrials.gov identifier NCT00534443). Results: At the end of treatment sTREM-1 was either: (a) below the limit of detection (this occurred in 62 patients and it was accompanied by lacks signs of residual disease in 58 patients, 93.5%); or (b) above the limit of detection (this occurred in 17 patients and it was accompanied by residual disease in 14 patients, 82.3%) (p<0.0001). Odds ratio for complete healing of peptic ulcer with sTREM-1 below detection limit was 5.30 (95% CI: 1.89-14.83, p<0.001) compared to serum sTREM-1 above the limit of detection. Conclusions: Serum sTREM-1 below detection limit may effectively distinguish patients who successfully completed therapy for PUD from those with residual disease and apply as a surrogate marker. Springer Science+Business Media, LLC, 2011 sTREM-1 nationallicence Chronic gastritis nationallicence Peptic ulcer nationallicence Residual disease nationallicence Koussoulas Vassilios Department of Gastroenterology, Sismanogleion General Hospital, Athens, Greece aut Giamarellos-Bourboulis Evangelos 4th Department of Internal Medicine, University of Athens, Medical School, Attikon University Hospital, 1 Rimini Str., 12462, Athens, Greece aut Barbatzas Charalambos Department of Gastroenterology, Sismanogleion General Hospital, Athens, Greece aut Pimentel Mark GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA aut Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/12(2011-12-01), 3590-3595 0163-2116 56:12<3590 2011 56 10620 https://doi.org/10.1007/s10620-011-1761-4 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10620-011-1761-4 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Koussoulas Vassilios Department of Gastroenterology, Sismanogleion General Hospital, Athens, Greece aut NATIONALLICENCE 700 1- Giamarellos-Bourboulis Evangelos 4th Department of Internal Medicine, University of Athens, Medical School, Attikon University Hospital, 1 Rimini Str., 12462, Athens, Greece aut NATIONALLICENCE 700 1- Barbatzas Charalambos Department of Gastroenterology, Sismanogleion General Hospital, Athens, Greece aut NATIONALLICENCE 700 1- Pimentel Mark GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA aut NATIONALLICENCE 773 0- Digestive Diseases and Sciences Springer US; http://www.springer-ny.com 56/12(2011-12-01), 3590-3595 0163-2116 56:12<3590 2011 56 10620 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer